Developing microbiome ecosystem therapies to improve outcomes for patients with liquid tumours
Herve Affagard, Chief Executive Officer at MaaT Pharma, gives us an update on the clinical trials (Maat013 and Maat033) and describes the vision of the company for the future of the microbiome space.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
